BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33183012)

  • 21. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
    Li X; Tan Q; Li H; Yang X
    J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
    Wood SJ; Gao Y; Lee JH; Chen J; Wang Q; Meisel JL; Li X
    Breast Cancer Res Treat; 2024 May; 205(1):193-199. PubMed ID: 38286889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Neoadjuvant
    Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S
    In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
    Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
    Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
    J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis.
    Li S; Zhang Y; Zhang P; Xue S; Chen Y; Sun L; Yang R
    Breast; 2022 Dec; 66():97-109. PubMed ID: 36219945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
    Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
    Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.
    Talamantes S; Xie E; Costa RLB; Chen M; Rademaker A; Santa-Maria CA
    Cancer Med; 2020 Oct; 9(19):6954-6960. PubMed ID: 32757467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
    Inoue K; Nagai SE; Saito T; Sakurai T; Kimizuka K; Yamada H; Kuroda T; Hata S; Yamazaki Y; Kojima M; Futsuhara K;
    Invest New Drugs; 2020 Feb; 38(1):140-147. PubMed ID: 31289984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: Real-world data from a developing country.
    Sharma RK; Gogia A; Deo S; Sharma D; Mathur S; Sagiraju HKR
    Indian J Cancer; 2023 Oct; 60(4):505-511. PubMed ID: 38189648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer.
    Qian XL; Xia XQ; Li YQ; Jia YM; Sun YY; Song YM; Xue HQ; Hao YF; Wang J; Wang XZ; Liu CY; Zhang XM; Zhang LN; Guo XJ
    Sci Rep; 2023 Jun; 13(1):9256. PubMed ID: 37286786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer.
    Wu R; Oshi M; Asaoka M; Yan L; Benesch MGK; Khoury T; Nagahashi M; Miyoshi Y; Endo I; Ishikawa T; Takabe K
    Ann Surg; 2023 Oct; 278(4):587-597. PubMed ID: 37318852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
    Cerbelli B; Botticelli A; Pisano A; Pernazza A; Campagna D; De Luca A; Ascierto PA; Pignataro MG; Pelullo M; Rocca CD; Marchetti P; Fortunato L; Costarelli L; d'Amati G
    Virchows Arch; 2020 Apr; 476(4):569-576. PubMed ID: 31853625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer.
    Huang K; Jakub J; Gabriel E; Moreno-Aspitia A; McLaughlin S
    Ann Surg Oncol; 2023 Nov; 30(12):7026-7035. PubMed ID: 37490162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
    Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
    Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.